ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Precision BioSciences raises $110 million for off-the-shelf CAR-T and gene-edited crops

by Ryan Cross
July 8, 2018 | APPEARED IN VOLUME 96, ISSUE 28

 

Precision BioSciences has raised $110 million in series B financing to advance a drug discovery program using Arcus, its homing endonuclease-based gene-editing tool. Homing endonucleases are enzymes, used by scientists years before CRISPR gene editing was invented, that recognize and cut DNA sequences. The Durham, N.C.-based firm will use the funds to move its lead therapy program, off-the-shelf CAR-T cancer treatments, into the clinic and begin field tests of crops edited with Arcus.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment